|
|
Preparation "adimast" for treatment of mastitis in cows in dry period Preparation comprises apramycin, xanthan gum, dioxidine, glycerin, and distilled water in the following ratio of components, wt %: apramycin - 6.8; dioxidine - 1.0; xanthan gum - 0.2; glycerin - 3.0; distilled water - 89. |
|
|
Preparation "dioksomast" for treatment subclinical mastitis in cows Preparation comprises dioxidine, xanthan gum, lactam tetramethylenediethylenetetramine, distilled water, prednisolone in the following ratio of components, wt %: dioxidine - 1.0; xanthan gum - 0.18; lactam tetramethylenediethylenetetramine - 3.0; prednisolone - 0.7; distilled water - 95.12. |
|
|
Iodine-containing preparation and its use Preparation comprises an antiseptic stimulant of Dorogov (ASD) of fraction 2, the iodine-containing active ingredient is used as the mixture of iodine-bismuth sulphamide M and polymeric iodine-bismuth sulphamide, the basis - as crystalline methyl cellulose and distilled water at the following ratio of components: iodine-bismuth sulphamide M in powder - 20-45 g, polymeric iodine-bismuth sulphamide - 20-50 g, antiseptic stimulant of Dorogov (ASD) of fraction 2-5 g, crystalline methyl cellulose - 20-30 g, distilled water - up to 1 l. The method comprises intrauterine administering of the claimed preparation daily for 5-6 days at a dose of 150 ml once a day. |
|
Method of conservative phimosis treatment Phonophoresis of androgen-containing oily preparations on external orifice of prepuce is realised. Impact is performed in accordance with labile method with radiation frequency 880 Hz with working surface 0.5 cm2, intensity 0.4 W/cm2, with continuous mode of ultrasound fluctuations. Duration of procedure constitutes 6 minutes. Procedures are carried out every second day for 1-2 weeks. |
|
|
Method of lymphotropic therapy of mastitis in cows Method comprises administering alternately in lymphotropic way through one needle of solutions 6.4 ME hyaluronidase dissolved in 1 ml of 0.5% novocaine solution, then 500000 ME roncoleukine dissolved in 50 ml of 0.9% sodium chloride solution, and then half the daily dose of 2.5% Kobaktane in the nipple bed area of the affected udder parts 3 times with an interval of 24 hours. |
|
Method of treating cervical ectopia One months before a coagulation procedure on the third day of menstrual cycle, a course of immunotherapy with pyrogenal is conducted. The course starts with a dose of 25 mcg intramuscularly every 48 hours. The dose is gradually increased by 25 mcg until a body temperature increases to min. 38°C, but no more than a maximum dose of pyrogenal of no more than 150 mcg. Once the temperature increases, a combination antibacterial, antiprotozoal, antimycotic and antiviral therapy combined with the preparation Galavit starts. The latter is used in the form of rectal suppositories in a dose of 100 mg during 10 days. The coagulation procedure is performed on the second day after the following menstruation terminates. On the third, fifth and seventh post-coagulation day, the cervix is processed with the preparation Galavit in the form of 100 mg of a dry substance dissolved in 5 ml of Miramistin with inserting a tampon wetted in the solution for 5 hours. |
|
Method for integrated treatment of adhesive process in small pelvis in females Method involves thermal and mechanical exposure on lower abdomen and lumbosacral spine taking into account the localisation and prevalence of the adhesive process in the small pelvis, and vaginal administration of a therapeutic solution. The 10-minute thermal exposure represents placing thermocompressors S = 980 cm2 each, heated to 48-50°C onto the lower abdomen and lumbosacral spine. That is followed by manual gynaecological massage to eliminate right- or left-side adhesive process by performing the following techniques: second and third fingers of right hand are inserted into vagina and moved to right or left vaginal wall respectively; fingers of left hand are placed above a projection of appendages on the right or on the left respectively on an anterior abdominal wall; fingers of right hand are brought apart with executing stretching motions between uterus and appendages and massaging circular motions with fingers of left hand from above. Fingers of right and left hands execute massaging motions so as trying to place them above each other; rotational directed motions are executed to move uterus to the left or to the right respectively. The adhesive process between intestine and posterior wall of uterus is eliminated by the following techniques: fingers of right hand are inserted into vagina behind neck of uterus into posterior vaginal vault to lift uterus slightly; fingers of left hand are brought behind uterus from the side of abdominal wall; massage is performed with circular motions, whereas fingers of right and left hands are connected together. A saltosalpinx is eliminated with evacuating fluid from uterine tube into uterus and further into vagina by massaging from fimbrial to uterine end of uterus. The manual gynaecological massage is followed by vaginal administration of the therapeutic solution in the form of "Sakskoye Lake" sulphide silt therapeutic mud heated to 48-50°C in an amount of 90 ml to be removed 20-30 min later. |
|
|
Using intravaginal insulin sensitisers Group of inventions refers to medicine, namely gynaecology and endocrinology, and can be used for treating polycystic ovarian syndrome, ovarian hyperandrogenism and/or related disorders. Using according to the invention involves an insulin sensitiser for producing a vaginal medicinal product. Methods according to the invention involve the vaginal administration of the insulin sensitiser. Pharmaceutical compositions according to the invention contain the insulin sensitiser for vaginal administration. |
|
Method of prevention and treatment of vulvovaginitis and vaginitis Invention relates to medicine, namely to obstetrics and gynaecology, and can be used for the sanitation of the mucosa and recovery of vaginal biocenosis in case of non-specific and vulvovaginal candidiasis and vaginoses in gynaecological practice, including the period of pregravidary preparation, in obstetrics - for the correction of vaginal dysbiosis in pregnant women. The method of prevention and treatment of vulvovaginitis and vaginosis, including pregnant women, consists in the following: at the first stage the irrigation of external genitalia with the solution "Malavit" is performed, at the second stage a loose gauze pad, also soaked in the "Malavit" solution, is introduced into the posterior vaginal fornix, with the application of the water "Malavit" solution with 1/20 dilution, with the preliminary application of the "Malavit" cream-gel on a gauze pad at the second stage. The method has 90% efficiency with the recovery of physiological vaginal biocenosis in gynaecological patients and pregnant women with non-specific and vulvovaginal candidiasis, bacterial vaginosis. |
|
|
Invention relates to medicine, namely to a method of preventing infectious and inflammatory complications in women with submucosal uterine myoma after hysteroresectoscopy. The essence of the method consists in the following: after hysteroresectoscopy antibiotics, probiotics and prebiotics are applied for not less than 3 days, where enterol -250 is applied as the probiotic, and hylak forte is applied as the prebiotic. |
|
|
Method of treatment of endometritis in cows Method of treatment of endometritis in cows comprises administering an antimicrobial agent into the uterus - the emulsion consisting of sterile sunflower oil, the agent ASD-3, tea tree essential oil, infusion of hellebore for animals, with the following component content, ml: sterile sunflower oil 890; the agent ASD-3 50; tea tree essential oil 25; infusion of hellebore for animals 35, the resulting emulsion is kept at room temperature for one day, prior to administering the emulsion is heated to the temperature of 38-39°C, administered at a dose of 80-100 ml per animal 2-3 times with an interval of 48 hours. |
|
|
Method of treating chronic endocervicitis After cervical canal is treated with 0.02% methylene blue, cefoperazone is instilled in an amount of 1.0 g of powder dissolved in 2.0 ml of water for injections. The therapeutic course is 4 or 5 procedures every second day. |
|
Method of fertility improvement of eastern mink and viability of offspring Invention is intended to increase the fertility of eastern mink Standard (+/+ +/+), and the viability of its offspring. The method comprises the use of the agent Biostim. Biostim is used for females and males prior to oestrum for 5 days and during the oestrum three times every second day at a dose of 0.05 ml/kg body weight. |
|
Agent for stimulating reproductive function What is presented is using 2-[1-(1,1-dioxothietanyl-3)benzimidazolyl-2-thio]acetic acid potassium salt (formerly known as an immunotropic and anxiolytic agent) as an agent to stimulate the reproductive function: prolonging an oestrus phase and shortening a proestrus phase of the ovulatory cycle activating receptive sexual motivation and impregnation processes, reducing the pre- and post-implantation embryo death. |
|
Treating polycystic ovarian syndrome in adolescent girls having the normal body weight, however no metabolic-endocrine comorbidity and active and sub-compensated chronic extragenital diseases, with the use of non-hormonal preparations is ensured by prescribing two non-hormonal target herbal preparations from the first day of spontaneous or gestagen-induced menstruation: indinol 600 mg twice a day and epigallat 1,000 mg twice a day continuously over a period of 6 months. |
|
|
Homeopathic suppositories applicable for treating gynaecological and urological diseases, based on natural producers and containing cacao butter, wax, highly mineralised mud of West Siberia lakes, anhydrous lanolin, aloe extract, white cedar oil in certain proportions. |
|
|
Aqueous composition, containing follicle-stimulating hormone Invention relates to chemical-pharmaceutical industry and represents aqueous composition for stabilisation of follicle-stimulating hormone, which includes follicle-stimulating hormone and combination of histidine and methionine as stabilising means, where histidine concentration constitutes from 0.05 to 10.0 mg/ml and concentration of methionine constitutes from 0.05 to 10 mg/ml, sucrose and phosphate buffer substance. |
|
Invention relates to the application of a pharmaceutical composition for local application for the prevention of sexually transmitted viral diseases, which includes an effective quantity of a formula (I) compound. The composition is applied locally into the vagina, anus or oral cavity. In formula (I) R1, R2 and R3 represents hydrogen. The invention also relates to the application of the pharmaceutical composition, made in the form of a vaginal cream, and to the application of a condom, covered with the said pharmaceutical composition. |
|
Method of treating acute postpartum endometritis Treating acute postpartum endometritis involves 2-staged regional antibacterial therapy. The first stage involves the subcutaneous administration of a combination of drug preparations: Lydase 16 units+2% lidocaine hydrochloride 1 ml, within the inguinal regional lymph glands. Keeping the needle inside, ceftriaxone 0.5 g in 2% lidocaine hydrochloride 1 ml is administered into the same region. At the second stage, regional lymphotropic therapy is conducted by feeding low-frequency ultrasound. To this effect, gauze tampons 10×10 cm soaked in a medicinal mixture containing Lydase 16 units+2% lidocaine hydrochloride 1 ml and ceftriaxone 0.5 g are placed onto the skin within a projection of the superficial inguinal ring. Sonic phoresis of this region is performed within 25 seconds at a frequency of 0.88 MHz. The therapeutic course makes 5 daily procedures. |
|
|
Method of treating patients with chronic endometritis and tubal and peritoneal infertility factor Method involves antibacterial, antimycotic, antiviral therapy taking into account sensitivity and recovered pathogenic flora and/or immune-enhancing therapy. From the 3rd day of the above therapy, local treatment involving the intrauterine insertion of a device for administering a complex of preparations and the prescribed hormone therapy is conducted. The device for administering the complex of preparations is presented by the Foley catheter, which is used to administer Miramistin 5 ml daily, Cefazoline or Ceftriaxone 4-6 minutes later, then Derinate 5 ml 4-6 minutes on even days, Longidaza 3 thousand units on odd days; the procedure is immediately followed by inserting a Miramistin tampon vaginally for 1-2 hours; one capsule of Polygynax is inserted vaginally for the night, whereas the hormone therapy is prescribed after the treatment. |
|
|
Salt of condensed heterocyclic derivative and its crystals Invention relates to novel choline salt of 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid, corresponding to formula and to its crystalline form. Crystalline form of salt (A) has characteristic peaks at diffraction angles (2θ(E)) 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5 and 26.2 in diagram of powder diffraction of X-rays, characteristic peaks of values of chemical shifts (δ(ppm)) 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1 and 55.5 in solid-state 13C NMR spectrum and characteristic peaks of values of chemical shifts (δ(ppm)) -131.6, -145, and -151.8 in solid-state 19F NMR spectrum, as well as endothermic peak about 213°C in diagram of differential-thermal analysis. |
|
Treatment of vaginal atrophy in women with risk of cardiovascular pathology Group of inventions relates to medicine, namely to gynaecology, and can be used for a method of prevention and/or treatment of urogenital atrophy in women, including the vaginal introduction of pharmaceutical compositions with estriol, as well as for the application of estriol in the production of a pharmaceutical composition with a possibility of self-restriction of estriol absorption. The said women have the high possibility of development of a cardiovascular pathology, or suffer or suffered from the cardiovascular pathology. Estriol is introduced in a dose, smaller or equal to 0.1 mg/day. An area under the estriol concentration curve depending on the time constitutes less than 500 pg/ml·h after the introduction of repeated doses one time per day for the time period from 1 to 4 weeks. |
|
Pyrazolopyrimidine compound for treating erectile dysfunction Invention refers to a compound (I) or its pharmaceutically acceptable salt, which possess properties of selective phosphodiesterase inhibitors, and can be used for treating male erectile dysfunction. In compound (I) R1 represents C1-C6alkyl; R2 represents C1-6alkyl; R3 represents C1-C6alkyl; R4 represents C1-C6 alkyl; R5 means H. The above salt is formed by the compound of formula (I) and an acid specified in citric acid, oxalic acid, hydrochloric acid, sulphuric acid, phosphoric acid, maleic acid, fumaric acid, tartaric acid, hydroxysuccinic acid, succinic acid, methane sulphonic acid or n-toluene sulphonic acid. A preferential compound is 5-[2-ethoxy-5-(4-methyl-1-homopiperazinylsulphonyl)]phenyl-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one. |
|
Phenoxy-substituted pyrimidines for application as opioid receptor modulators Invention relates to novel compounds of formula |
|
4-substituted-2-phenoxyphenylamine modulators of delta-opioid receptors Invention relates to novel compounds of formula I, possessing ability of binding with delta-opioid receptors. In formula R1 is selected from the group, consisting of i) phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxyl, di(C1-4alkyl), aminocarbonyl, chlorine and fluorine, in such a way that only one di(C1-4alkyl)aminocarbonyl is present; ii) naphthyl; iii) pyridinyl, optionally substituted with one substituent, selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxy, fluorine, chlorine and cyano; iv) pyrimidin-5-yl; v) furanyl; vi) thienyl; vii) 5-oxo-4,5-dihydro-[1,2,4]oxodiazol-3-yl; and viii) di(C1-2alkyl)aminocarbonyl; Y represents ethyl, vinyl or bond; or Y represents O, when R1 represents optionally substituted phenyl, where substituent represents C1-4alcoxy; R2 represents phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, fluorine, chlorine and cyano, trifluoromethoxy and hydroxy; or R2 represents phenyl, substituted with one aminocarbonyl, di(C1-4alkyl)aminocarbonyl, C1-4alcoxycarbonyl or carboxysubstituent; R3 is selected from the group, consisting of i) 3-aminocyclohexyl; ii) 4-aminocyclohexyl; iii) piperidin-3-yl; iv) piperidin-4-yl; v) pyrrolodin-2-yl-methyl, in which pyrrolodin-2-yl is optionally substituted by 3-rd or 4-th position with one or two fluorine-substituents; vi) azetidin-3-yl; vii) 2-(N-methylamino)ethyl; viii) 3-hydroxy-2-aminopropyl; ix) piperidin-3-yl-methyl; x) 1-azabicyclo[2.2.2]octan-3-yl; and xi) 8-azabicyclo[3.2.1]octan-3-yl; or R3 together with Ra and nitrogen atom, which they both are bound to, form piperazinyl, optionally substituted with 4-C1-4alkyl; Ra represents hydrogen, 2-(N-methylamino)ethyl or C1-2alkyl, optionally substituted with azetidin-3-yl. |
|
Group of inventions relates to the field of animal husbandry and is intended for stimulation of energy metabolic processes and to the method of prevention of patrimonial pathologies and postnatal diseases at cows. The offered composition for stimulation of energy metabolic processes includes the use of amber acid as an energy stimulator. A carbohydrate component is beet treacle, it is used in the following ratio of components per 1 litre: amber acid - 15 g, beet treacle - 500 g, water - the rest. The offered method includes the administration of the named composition a days before calving and during the first hours after calving. |
|
Presented egg-shaped vaginal suppositories contains the following mass ratio in 1 capsule (egg-shaped vaginal suppository): sulphadimine 0.05 g; metronidazole 0.01 g, potato starch 0.02 g, glucose 0.04 g, 5% polyvinyl alcohol 0.07 g, 15% oily extract of propolis 1.0 g; gelatine 0.2 g; dimethicone 0.04 g; glycerol 0.4 g; purified water 0.37 g. |
|
Method of treating chronic abacterial prostatitis complicated by sexual dysfunction Combined phyto- and physiotherapy is conducted. The phytotherapy involves administering Prolit Super 2 capsules two times a day (at 8 and 14 o'clock) for one month; the physiotherapy provides rectal electrical stimulation by means of AndroGyn for 8 minutes a day, 15 procedures in the therapeutic course. |
|
N-acetyl-l-cysteine for treatment of endometriosis Invention relates to a method of treating a mammal with endometriosis. The claimed method includes the pulse or interrupted peroral introduction of an N-acetyl-L-cysteine-containing pharmaceutical composition for 3-5 successive days with the following 2-4-day break or for 1-3 successive days with the following 1-2-day break, for at least a two-month time period. N-acetyl-L-cysteine in the said method is introduced in a dose, constituting from 20 to 90 mg/kg/day. |
|
Method of preventing postpartum inflammatory diseases of uterus and mammary glands of cows Method comprises intramuscular administration in the body of the medicinal drug of antioxidant action prior to anticipated calving twice. The first administration is performed 50÷60 days before. The second administration is carried out 15÷20 days prior to anticipated calving. The medicinal drug is used as immunofan which is administered in a dose of 4÷5 ml per animal. |
|
|
Method of treating diffuse mammary dysplasia in females of reproductive age Problem is solved by prescribing patients a preparation of a 1% alcoholic gel of testosterone in the period from 12 to 15 o'clock in a dose of 0.5 ml once a day transdermally for 3 months. The new about the presented method is using testosterone in a dose of 0.5 ml in the period from 12 to 15 o'clock. |
|
|
Method of treatment of mastitis in lactating sheep Method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%. |
|
|
Compound possessing inhibitory action on phosphodiesterase type 5, and method for preparing it Present invention refers to a citrate of a compound described by formula (II) below, and a pharmaceutical composition containing said citrate. |
|
Group of inventions refers to medicine and concerns a stable composition of nanostructured Sildenafil inhibiting cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDEV) containing a nanostructured Sildenafil base or its pharmaceutically acceptable salts having an average particle size of less than approximately 500nm, a stabilising agent, wherein the composition is prepared in a microfluidics-based continuous-flow tank reactor, and the composition possesses a semi-amorphous structure. The group of inventions also concerns a method for preparing the composition of nanostructured Sildenafil; using the above composition for preparing the pharmaceutical composition for treating male or female sexual dysfunction and pulmonary arterial hypertension. |
|
Chromone derivatives, method for preparing them and therapeutic uses thereof Invention refers to new chromone derivatives of general formula |
|
Method involves reproducing simulated gestosis experimentally by the intraperitoneal administration of N-nitro-L-arginine-methyl ester (L-NAME), an ADMA-like endothelial NO-synthase blocker in a dose of 25 mg/kg into pregnant female Wistar rats for 7 days from the 14th to 20th day of pregnancy. That is combined with the daily intragastric administration of Nicorandil through a probe in a dose of 10 mg/kg 2 times a day for 7 days from the 14th to 20th day of pregnancy. |
|
|
Birth control technique used as and when necessary Invention refers to medicine, gynaecology, birth control techniques used as and when necessary, and emergency contraception. Ulipristal acetate or its metabolite is administered orally in a female no more than 72 hours to 120 hours after a sexual encounter in a dose of 20 to 30 mg. Another dose can be administered again at least twice a month. The preparation can be administered either in the form of an immediate-release dosage form, in the form of a tablet. |
|
Medication for treating erectile dysfunctions and method of treating erectile dysfunctions Invention relates to medicine, namely to urology, and deals with treatment of erectile dysfunction. For this purpose pharmaceutical composition, containing activated potentiated form of antibodies to prostate-specific antigen and as additional enhancing component - activated potentiated form of antibodies to endothelial NO-synthase. |
|
|
Method for integrated treatment of external genital endometriosis Surgical intervention is followed by prescribing letrozole 2.5 mg once a day and linestrenol 0.5 mg 2 times a day continuously for the period of 6 months. |
|
|
New phenol derivatives and their pharmaceutical or cosmetic application Invention refers to compounds of structural formula (I), which can be used for treating diseases mediated by an androgen receptor. In formula (I), R1 means (C2-6)alkyl, (C1-6)alkyloxy, -S(O)m-(C1-6)alkyl, (C1-6)fluoroalkyl, CN or halogen, R2 and R3 are identical or different and mean a hydrogen atom or (C1-9)alkyl, R4, R5, R6, R7 are identical or different and mean a hydrogen or halogen, X means CH or N, Y means either a nitrogen atom, or a carbon atom substituted by (C1-6)alkyl, (C1-6)alkyloxy, (C1-6)fluoroalkyl, a hydrogen atom or halogen; m is equal to 0, 1 or 2. |
|
Invention refers to compounds of formula (I) - oxytocin receptor agonists, to their pharmaceutical compositions containing them. |
|
Diagnostic technique for transport dysfunction of uterine tubes Invention refers to medicine, namely to gynaecology, and can be used for diagnosing the transport dysfunction of the uterine tubes. That is ensured by hysteroscopy accompanied by inserting catheters into the uterine cavity within openings of the uterine tubes, bringing them out through the vagina and fixing to the inner thigh. A colour solution is introduced into the abdominal cavity through a puncture of the posterior vaginal vault. That is followed by a double-side block of the round ligament of the uterus with the anaesthetic solution in an amount of 15.0 ml every 4-6 hours. Keeping the transport function is shown by observing the colour solution 24 hours later in the catheter lumen. The transport dysfunction of the uterine tubes is shown by no ingress of the colour solution into the catheter. |
|
|
Method of prevention of postpartum endometritis in cows Method comprises intravaginal administration of probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574). "Giprolam" is administered for 5-7 days prior to calving daily at a dose of 100 cm3. |
|
|
Method of treatment of subclinical mastitis in lactating cows Method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml. |
|
|
Method of treatment of endometritis in animals Chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids. |
|
Method of treatment of endometritis in animals Method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids. |
|
Method of treating subclinical mastitis in cows Invention refers to agriculture, particularly to veterinary medicine, and aims at providing the more effective mosquito puncture procedures for the purpose of treating subclinical mastitis in cows by the effect of mosquitoes on biologically active points. That is ensured by the fact that the exposure covers the biologically active points from both sides of a sacral bone by introducing 20 mosquitoes for 4-5 minutes. The procedures are performed four times every 24 hours. |
|
|
Method of treating latent mastitis in cows Invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day. |
|
|
Method for local treatment of inflammatory diseases of uterine cavity and device for implementing it Group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm. |
|
Agent for treating and preventing endometritis in animals Invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals. |
Another patent 2551035.